GSTM3

Across TCGA pan-cancer cohorts, GSTM3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GSTM3 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GSTM3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GSTM3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where GSTM3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.865	0.585	.005	36	view →
CCRCC	OS	Median	III,IV	0.863	0.502	.002	27	view →
LSCC	DFS	Tertile	All	0.893	0.661	.009	18	view →
HNSC	OS	Median	II,III,IV	0.613	0.807	.006	15	view →
UCEC	OS	Median	II,III,IV	0.590	1.000	.007	12	view →
GBM	OS	Quartile	All	0.176	0.634	.003	6	view →
LUAD	OS	Tertile	All	0.912	0.591	.012	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GSTM3–PDAC (DFS)

Open the PDAC breakdown →